European Journal of Endocrinology Disclosure Policy
(last updated May 2017)

All editors responsible for recommending or making publication decisions are requested to disclose on an annual basis any potential conflict of interest, including current or recent financial relationships with any commercial entity whose products or services may be contained in the journal content.

The following competing interests were disclosed:

Kåre I Birkeland – has received payment from Novo Nordisk, Eli Lilly, Sanofi – Aventis, MSD, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer for participation at scientific meetings. He is also a member of advisory boards, steering committees or data safety committees for Novo Nordisk, MSD, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen AS. He has received reimbursements for chairing the Medical Advisory Committee of the Norwegian Diabetes Association. He is a member of The Norwegian Directorate of Health’s standing National Advisory Committee for Diabetes and in developing the Norwegian guidelines for the treatment of diabetes.

Cesar Luiz Boguszewski – is President of International Committee, Brazilian Society of Endocrinology and Metabolism, and receives no compensation. He is a member of the council (clinical scientist seat), The Endocrine Society, for which he receives no compensation. He is also associate editor for South America, and receives honoraria compensation. He is Director, Pituitary Society (2014-2017), no compensation. He does not receive compensation for being a member of the European Society of Endocrinology and the Growth Hormone Research Society. He has received compensation for being speaker/consultant of Novartis oncologia, Pfizer and Ipsen.

Philippe Caron – has been a consultant for Ipsen Lab, Merck Serono Lab and Pierre Fabre Lab. He has received personal fees from Pierre Fabre, Ipsen, Merck Serono, HAC, Novartis and Pfizer. Prof Caron is also on the advisory board for Ipsen.

Martin Fassnacht - Publication Core Committee of the Endocrine Society (until 2018) German Society of Endocrinology – elected member of ExCo (until June 2017) European Network for the Study of Adrenal Tumors (ENSAT) – Chair (since 2016) and was Head of the Adrenocortical Carcinoma Working group until 2016 European Society of Endocrinology - member of the clinical committee (until 2017) None of these positions is financially compensated.

Ken Ho - advisory board member of Novartis, Pfizer and Versartis. He has also received funding from Novo Nordisk and Versartis.

Gudmundur Johannsson – has been a consultant for AstraZeneca, Novo Nordisk and Shire, and has received lecture fees from Merck Serono, Novo Nordisk, Novartis, Otsuka, Pfizer and Shire.

Bente Langdahl – is on the advisory board of Amgen, Eli Lilly, MSD and UCB and has received research grants from Eli Lilly, Novartis, Novo Nordisk and Orkla Health.

Juliane Léger – is an investigator in a clinical trial using growth hormone (GH) sponsored by Novo-Nordisk and support for travel to international meetings from several GH manufacturers.

Antoine Tabarin – occasional consultant and speaker for Ipsen Biotech, Novartis pharma and HRA Pharma.

Jeremy Tomlinson - Scientific advisory board and consultancy for Poxel SA

Andrea Isidori – has received consultancy fees and unrestricted grants from Novartis and Shire
The following editors reported no competing interests:
Maria Alevizaki
Marianne Andersen
Olaf Dekkers
Evanthia Diamanti-Kandarakis
Laura Fugazzola
Jose Moreno
Peter Nightingale
Johannes Romijn
Jenny Tong
Ernesto Canalis

Bioscientifica staff and freelancers working on the journal reported no conflicts of interest. Article authors' declarations are stated in each journal article. Referees must disclose any competing interests before agreeing to review any submission. For more information on the journal’s ethical policy, please read the ethical guidelines.

This policy follows the recommendations of the International Committee of Medical Journals Editors (ICMJE) and the Committee on Publication Ethics (COPE).